Genesis Therapeutics, an AI drug discovery startup, has entered into a collaboration with Genentech, a wholly-owned biotechnology subsidiary of Roche Group, to support identification of new drug candidates across a range of diseases.
Genentech will gain access to Genesis’ AI platform and other neural network algorithms that aim to predict how well molecules bind with moving protein chains. This will help the company develop therapeutics for targets previously classified as undruggable.
Genesis will receive an undisclosed amount as an upfront payment. The company may also receive preclinical, clinical and regulatory milestone payments and royalties on sales of therapeutics developed through the collaboration.
Founded in 2019, Genesis Therapeutics is a Stanford University spinout company that claims to offer low cost AI drug discovery services. It secured seed funding of USD 4.1 million in November 2019.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.